The Biologics News and Reports Portal

Show Cart

Biosimilar Antibodies & Proteins

Results 1 - 10 of 22

Dec 2019 Competitor Analysis: Next Wave Biosimilar Antibodies of Lucentis, Eylea, Xolair, Prolia, Stelara, Soliris and More

600.00 €

Nov 2017 Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2017 Update

450.00 €

Mar 2017 Competitor Analysis: Complement C5 Inhibitors 2017 - Biosuperiors & Biosimilars

200.00 €

Jun 2016 Therapeutic Antibody Reports Bundle: ADCs, Bispecifics, Biosimilars & Biosuperiors

3,100.00 €

6,200.00 €

(Discount: 50.00%)

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update

250.00 €

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update

300.00 €

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update

300.00 €

Start
Prev
1
2
3
Next
End

Shopping cart

Cart empty

Latest report

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Featured Products

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Report Package: “Drug the Undruggable” Technologies

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Latest Target Pipeline

STING Agonists & Antagonists

Shopping cart

Cart empty

Latest report

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Featured Products

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Report Package: “Drug the Undruggable” Technologies

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Biosimilar Antibodies & Proteins

Dec 2019 Competitor Analysis: Next Wave Biosimilar Antibodies of Lucentis, Eylea, Xolair, Prolia, Stelara, Soliris and More

Nov 2018 Neulasta Biosimilars – Target Pipeline List 11/2018

Nov 2018 Avastin Biosimilars - Target Pipeline List 11/2018

Nov 2018 Humira Biosimilars – Target Pipeline List 11/2018

Nov 2017 Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2017 Update

Mar 2017 Competitor Analysis: Complement C5 Inhibitors 2017 - Biosuperiors & Biosimilars

Jun 2016 Therapeutic Antibody Reports Bundle: ADCs, Bispecifics, Biosimilars & Biosuperiors

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

La Merie Biologics

FREE Weekly News Bulletin

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing